Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma.

BACKGROUND: Immunosuppression and Merkel-cell polyomavirus (MCPyV) infection may have a role in the pathogenesis of Merkel-cell carcinoma (MCC), a rare neuroendocrine carcinoma of the skin. METHODS: We studied incidence of chronic lymphocytic leukaemia (CLL) and MCC from the files of the Finnish Cancer Registry and the largest hospital of Finland, Helsinki University Central Hospital, from 1979 to 2006. Presence of MCPyV DNA in MCCs was investigated by quantitative PCR. RESULTS: We identified 4164 patients diagnosed with CLL and 172 diagnosed with MCC. Six patients diagnosed with both diseases were found; CLL was the first diagnosis in four cases and MCC in two. The standardised incidence ratio (SIR) for CLL after the diagnosis of MCC was highly elevated, 17.9 (95% confidence interval (CI), 2.2-64.6; P<0.001), and the SIR for MCC after the diagnosis of CLL was also elevated, 15.7 (3.2-46.0, P<0.01). Merkel-cell polyomavirus DNA was present in all five MCCs with tumour tissue available for analysis. CONCLUSIONS: We conclude that patients diagnosed with CLL have a substantially increased risk for MCC, and vice versa. Merkel-cell polyomavirus DNA is frequently present in MCCs that occur in CLL patients. Immunosuppression related with CLL and viral infection might explain the association between CLL and MCC.

Merkel cell carcinoma in a young pregnant woman.

SUMMARY: We present a 27-year-old pregnant woman with Merkel cell carcinoma on the forehead. In early pregnancy, the lesion was excised as an epidermal cyst. It was only after recurrence that a diagnosis of Merkel cell carcinoma was made. Sentinel-node biopsy, excision with 2 cm margins and reconstruction with free microvascular radial forearm flap was carried out, and the patient received postoperative radiotherapy. No evidence of recurrence or disease progression was found 24 months after surgery.

Prenatal care and counseling of female drug-abusers: effects on drug abuse and perinatal outcome.

BACKGROUND: To evaluate the efficacy of a specific counseling and withdrawal program for drug-abusing pregnant women and its effect on perinatal outcome. DESIGN AND SETTING: An analysis of 120 pregnancies followed in 111 drug-abusing women giving birth at the Department of Obstetrics and Gynecology, Helsinki University Central Hospital, in 1985-95. METHODS: Personnel responsible for local maternity care in the Helsinki area were trained to identify pregnant drug-abusers and to refer them to our hospital for clinical antenatal care and counseling with psychological and social support. Substance abuse during pregnancy was monitored by self-report and serial urine screenings. Obstetric and perinatal outcome were compared between those who succeeded in quitting totally or reducing drug use, and those who continued their drug use throughout pregnancy. The significance of the differences was tested by Student's unpaired t-test and binomial t-test. RESULTS: Of the women, 62% registered before the 20th week of pregnancy and 32% during the 20th-29th week of pregnancy (mean 18.4+/-6.6 weeks). Twelve women were admitted to an obstetric ward for withdrawal. In 73 of the 120 (61%) pregnancies the woman succeeded either in quitting totally or reducing drug abuse. Among this group, incidence of preterm birth (4.1%) was smaller (p<0.001), and gestational age (39.8+/-2.2 weeks) and birth weight (3393+/-605 gr) higher (p<0.05) than those (19.6%, 38.3+/-3.4 wk and 3049+/-728 gr, respectively) in the group continuing their drug abuse. Additionally, the percentage of normal delivery (80.8%) was higher (p<0.05), and incidence of withdrawal symptoms (19.2%), lower (p<0.001) than for those who continued drug abuse (65.2% and 47.8%, respectively). CONCLUSIONS: Carefully monitored counseling program for pregnant drug abusers is effective in reducing the amount of drugs used and improves perinatal outcome.